Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | RORC | P51449 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8180564 | 0.93 | RAB9A (0.88) | RAB9ANPC1POLBMAOBKMT2A | |
| SCHEMBL23747477 | 0.88 | RAB9A (0.78) | RAB9ANPC1POLBMAOBKMT2A | |
| SCHEMBL2831462 | 0.88 | NPC1 (0.77) | RAB9ANPC1POLBMAOBKMT2A | |
| SCHEMBL20911008 | 0.86 | RAB9A (0.75) | RAB9ANPC1POLBMAOBKMT2A | |
| SCHEMBL26099259 | 0.86 | RAB9A (0.75) | RAB9ANPC1POLBMAOBKMT2A | |
| SCHEMBL17000091 | 0.85 | NPC1 (0.73) | RAB9ANPC1POLBMAOBKMT2A | |
| SCHEMBL14025738 | 0.85 | NPC1 (0.73) | RAB9ANPC1POLBMAOBKMT2A | |
| SCHEMBL26546719 | 0.84 | RAB9A (0.73) | RAB9ANPC1POLBMAOBKMT2A | |
| SCHEMBL16946645 | 0.84 | NPC1 (0.84) | RAB9ANPC1POLBMAOBKMT2A | |
| SCHEMBL13720058 | 0.83 | NPC1 (1.00) | RAB9ANPC1POLBMAOBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574070-B | Synthesis method of substituted urea compound | 西华大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-112574070-A | Synthesis method of substituted urea compound | 西华大学 | 2021-03-30 | — | — | CN | disclosed |
| US-20190284171-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2019-09-19 | — | — | US | disclosed |
| WO-2019073484-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2019-04-18 | — | — | WO | disclosed |
| EP-0874823-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997023460-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284171-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | CBR3, CBR1, NOX3 | RAB9A 3010/4885NPC1 934/4885POLB 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.